Digital Therapeutics 2.0, Part Two: Connecting Users to Outcomes

By  Nate Beyor
Article

Once a digital therapeutics (DTx) company has determined the kind of value its software as a medical device (SaMD) provides, it needs to figure out which regulatory and commercialization strategies make the most sense.

Read the article